Suppr超能文献

bcl-2、p53和Ki-67蛋白在胰腺导管腺癌中的临床作用

Clinical contribution of bcl-2, p53 and Ki-67 proteins in pancreatic ductal adenocarcinoma.

作者信息

Mäkinen K, Hakala T, Lipponen P, Alhava E, Eskelinen M

机构信息

Department of Surgery, University Hospital and University of Kuopio, Finland.

出版信息

Anticancer Res. 1998 Jan-Feb;18(1B):615-8.

PMID:9568186
Abstract

The expression of apoptosis suppressing protein bcl-2, tumour-suppressor protein p53, and proliferation marker Ki-67 and their possible prognostic value were analysed in pancreatic ductal adenocarcinoma. Fifty-two % (34/64) of the samples were positive for bcl-2 and immunostaining were mainly localized in the cytoplasm of tumour cells. Bcl-2 expression was not related to tumour grade, DNA ploidy or S-phase fraction or to any clinical parameters. In univariate analysis bcl-2 expression predicted favourable outcome (p = 0.008). Positive nuclear staining for p53 was found in 40% (24/59) of samples and 80% (60/74) of the tumours were positive for Ki-67. p53 and Ki-67 expressions were not related to patient survival. According to our results, bcl-2 expression seems to be a predictor of disease outcome and may have some clinical value in human pancreatic cancer.

摘要

在胰腺导管腺癌中分析了凋亡抑制蛋白bcl-2、肿瘤抑制蛋白p53和增殖标志物Ki-67的表达及其可能的预后价值。52%(34/64)的样本bcl-2呈阳性,免疫染色主要定位于肿瘤细胞的细胞质中。bcl-2表达与肿瘤分级、DNA倍体或S期分数或任何临床参数均无关。单因素分析中,bcl-2表达预示着良好的预后(p = 0.008)。40%(24/59)的样本p53核染色呈阳性,80%(60/74)的肿瘤Ki-67呈阳性。p53和Ki-67表达与患者生存率无关。根据我们的结果,bcl-2表达似乎是疾病预后的一个预测指标,可能对人类胰腺癌具有一定的临床价值。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验